- Sinopec’s Q1 IFRS net are 18.72 billion yuan.
- There’s a decrease in IFRS net by 9.7%, down from 20.74 billion yuan in the corresponding period last year.
- The company reported a minimal decrease in revenue at 789.97 billion yuan, which is down by 0.2% compared to last year.
- Revenue failed to meet the estimate of 844.39 billion yuan as projected by 2 estimates.
- The company currently has 16 buys, 3 holds and no sells according to the latest analysis.
- All figures are based on the values reported by Sinopec’s original disclosures.
A look at China Petroleum & Chemical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts assessing the Smartkarma Smart Scores for China Petroleum & Chemical have provided a positive long-term outlook for the company. With top scores of 5 in both the Value and Dividend categories, this indicates strong potential in terms of the company’s value and dividend-paying capability. Additionally, a score of 4 for Growth suggests promising growth opportunities ahead, while a score of 3 for Resilience indicates a moderate level of resilience to market fluctuations. Furthermore, a Momentum score of 5 shows strong upward momentum in the company’s performance.
China Petroleum & Chemical Corporation, known for its production and trading of petroleum and petrochemical products, offers a diverse range of products including gasoline, diesel, synthetic fibers, and chemical fertilizers among others. With an expansive market presence in China, the company is well-positioned to capitalize on the growing demand for energy and petrochemical products domestically.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
